Ma CX, Luo J, Freedman RA, Pluard TJ, et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer. Clin Cancer Res 2022 Jan 19. pii: 1078-0432.CCR-21-3418.
PMID: 35046057